LCP4 treatment leads to the depletion of malignant HPCs. The absolute number of total JAK2V617F⁺ and homozygous JAK2V617F⁺ CFU-GM was calculated by multiplying the total number of CFU-GM by the fraction of JAK2V617F⁺ or homozygous JAK2V617F⁺ CFU-GM (Table 2), generated in cultures of JAK2V617F⁺ splenic or PB MF CD34⁺ cells treated with cytokines alone or cytokines plus LCP4 for 1 week. The percentage of the absolute number of total JAK2V617F⁺ and homozygous JAK2V617F⁺ CFU-GM generated in cultures of JAK2V617F⁺ splenic or PB MF CD34⁺ cells treated with cytokines plus LCP4, relative to that generated in cultures treated with cytokines alone is shown. n = 5. ***P < .001.